Trial reportAmerican journal of respiratory and critical care medicine2024
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.
Abstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative efficacy and safety of monotherapy and combination pharmacotherapies for idiopathic pulmonary fibrosis: a network meta-analysis of randomized controlled trials.BMC pulmonary medicine · 2026Pooled it
- Targeted therapy for idiopathic pulmonary fibrosis: a bibliometric analysis of 2004-2024.Frontiers in medicine · 2025Pooled it
- Dual αAmerican journal of respiratory and critical care medicine · 2025Trial
- Bexotegrast Shows Dose-Dependent Integrin αAnnals of the American Thoracic Society · 2025Trial
- Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy.International journal of molecular sciences · 2026Review
- Aberrant and ectopic cell populations in restrictive allograft syndrome after lung transplantation.The European respiratory journal · 2026Article
- Non-Resolving Repair in Idiopathic Pulmonary Fibrosis: From Failed Cellular Transitions to Architectural Lock-In.International journal of molecular sciences · 2026Review
- Article
- Advances in pharmacotherapy for fibrotic interstitial lung disease.Medical review (2021) · 2026Review
- Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics.BMJ open gastroenterology · 2026Review
- Cellular Senescence: Emerging Therapeutic Target for Idiopathic Pulmonary Fibrosis Pathogenic Mechanisms and Therapeutic Strategies.Biomolecules & therapeutics · 2026Review
- From force to fate: Implications of mechanomemory in lung disease.Respiratory research · 2026Review
- Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies.Journal of clinical medicine · 2026Review
- Single-cell insights into maladaptive endothelial plasticity and therapeutic targets in diabetic vascular complications.Cardiovascular diabetology · 2026Review
- HDAC8-mediated CAPZB desuccinylation enhances cytoskeleton remodeling to promote idiopathic pulmonary fibrosis.Communications biology · 2026Article
- Tweaking the Complex Fibrogenic Role of Lymphocytes in Idiopathic Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Article
- Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.BMJ open respiratory research · 2026Article
- Emerging Therapies in Pulmonary Fibrosis.Pulmonary therapy · 2026Review
- Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.Research square · 2026Article
- Bidirectional fibrogenic cross-talk revealed in a human iPSC-derived epithelial-mesenchymal co-culture model of pulmonary fibrosis.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Lisa LancasterDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Vincent CottinNational Reference Centre for Rare Pulmonary Diseases (Orphalung), Louis Pradel Hospital, ERN-LUNG, Lyon, France.ORCID 0000-0002-5591-0955
Murali RamaswamyPulmonIx, LLC, at Cone Health, Greensboro, North Carolina.
Wim A WuytsDepartment of Pneumology, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Leuven, Belgium.
R Gisli JenkinsNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Mary Beth ScholandDivision of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah Health, Salt Lake City, Utah.
Michael KreuterPneumology Department, Mainz Lung Center, Mainz University Medical Center and Marienhaus Clinic Mainz, Mainz, Germany.
Claudia ValenzuelaILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, Autonoma de Madrid, Madrid, Spain.
Christopher J RyersonDepartment of Medicine and Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada.
Jonathan GoldinDepartment of Radiology, University of California, Los Angeles, California.
Grace Hyun J KimDepartment of Radiology, University of California, Los Angeles, California.
Marzena JurekPliant Therapeutics, Inc., South San Francisco, California; and.
Martin DecarisPliant Therapeutics, Inc., South San Francisco, California; and.
Annie ClarkPliant Therapeutics, Inc., South San Francisco, California; and.
Scott TurnerPliant Therapeutics, Inc., South San Francisco, California; and.
Chris N BarnesPliant Therapeutics, Inc., South San Francisco, California; and.
Hardean E AchneckPliant Therapeutics, Inc., South San Francisco, California; and.
Gregory P CosgrovePliant Therapeutics, Inc., South San Francisco, California; and.
Éric A LefebvrePliant Therapeutics, Inc., South San Francisco, California; and.
Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.
PLN-74809-IPF-202 Trial Investigators
Funding
Pliant Therapeutics
Abstract
PubMed holds no abstract for this paper.
Indexed as
Idiopathic Pulmonary FibrosisIndolesPyridonesAgedDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedTreatment OutcomeIndolesnintedanibpirfenidonePyridonesefficacyfibrotic diseaseIPFsafety
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.